Amanta Healthcare Ltd
Amanta Healthcare Ltd Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
1 of 3 strong
Not discussed on this call: fundraise, order book.
The short version
SteriPort Line 3 expected to contribute around INR120 crores annualized revenue, fully realized within 12 months post-commissioning (from August 2026). SteriPort Line 3 commissioning expected by August 2026, with annualized peak revenue of INR110-120 crores achievable within 12 months of commissioning.
From Amanta Healthcare Ltd's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- SteriPort Line 3 expected to contribute around INR120 crores annualized revenue, fully realized within 12 months post-commissioning (from August 2026).
- SteriPort projected to generate roughly INR70 crores in top line during the 7 months remaining in FY27 and about INR425 crores revenue at peak utilization in FY28 including SVP.
- SVP facility to commence operations by March 2027, expected to drive growth in export-focused products like inhalation, ophthalmics, and preservative-free unit doses.
- SVP export revenues anticipated to comprise 60%-70% from advanced regulated markets (UK, Ireland, EU, Australia, Canada).
- Future growth drivers for FY27-FY29: inhalation products, ophthalmics, diluents in advanced markets.
- Focus on expanding sterile dosage forms, including exploring other packaging materials and drug delivery mechanisms beyond plastic.
- Capacity expansions and formulation development pipeline (20 products) expected to support sustained growth over next 2-3 years.
- Interest expense expected to reduce by FY28 indicating easing capex cycle.
Profitability & Margins
See what Amanta Healthcare Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- SteriPort Line 3: Total capex of INR 90 crores; approx. INR 80 crores spent so far; commissioning expected by August 24-25, 2026.
- SVP Expansion: Total capex of INR 30 crores; about INR 7 crores spent so far; expected to be operational by March 2027.
- No immediate further capex planned for SteriPort beyond Line 3, despite demand-supply mismatch.
- Future exploration of other drug delivery mechanisms and packaging materials (e.g., glass) beyond current plastic packaging, with clarity expected by December 2026 or January 2027.
- Investment in formulation development team and new center under construction, intending 8-10 scientists and 3-4 regulatory affairs personnel for advanced markets.
- Solar power captive project capex contributing to slight interest expense increase; reduces monthly operational costs by approx. INR 75 lakh.
- Post-2027, focus will be on activity-centric investments to support existing capacity rather than large capex.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Amanta Healthcare Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Amanta Healthcare Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹77 Cr, net profit ₹6 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Amanta Healthcare Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Novartis India Ltd (Q1 FY27)
Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…
- IOL Chemicals & Pharmaceuticals Ltd (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
- Innova Captab Ltd (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
- Glenmark Pharmaceuticals Ltd (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
Frequently Asked Questions
What were Amanta Healthcare Ltd Q1 FY27 results?
SteriPort Line 3 expected to contribute around INR120 crores annualized revenue, fully realized within 12 months post-commissioning (from August 2026). SteriPort Line 3 commissioning expected by August 2026, with annualized peak revenue of INR110-120 crores achievable within 12 months of commissioning.
What is Amanta Healthcare Ltd share price analysis?
Amanta Healthcare Ltd currently shows a below-average growth signal. The stock trades at a P/E of 39.6 with a market cap of ₹607 Cr. Investors should review the full earnings analysis for detailed insights.
Is Amanta Healthcare Ltd planning capital expenditure?
SteriPort Line 3: Total capex of INR 90 crores; approx.
Keep Amanta Healthcare Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.